 MIRAMAR, Fla., June 22, 2021 GLOBE NEWSWIRE -- NuGenerex Immuno-Oncology NGIO a subsidiary of Generex Biotechnology Corporation OTCQB:GNBT Generex or the Company, an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care today announced that the company has received a 535 million valuation from an internationally recognized, independent valuation and appraisal firm that provides valuation advisory services and fairness opinions to public and private companies. NGIO received the valuation as of November 15, 2020, and since then has made significant progress in the vaccine development programs, including completion of the GMP manufacturing of the Ii-Key-SARS-CoV-2 vaccine to potentially increase this valuation. The final lot release of the COVID-19 vaccine from the manufacturer for use in clinical trials is scheduled for July. Stability studies are ongoing to support the IND, which is currently being compiled for submission to FDA. Contingent on FDA approval and the receipt of financing the final vaccine manufacturing process is commercial ready using a lyophilization method that produces a stable, powdered Ii-Key-SARS-CoV-2 vaccine that can potentially be shipped and stored at room temperature, providing a substantial commercial advantage. 